Editing Modafinil (section)

====Multiple sclerosis-related fatigue====
The UK's [[National Institute for Health and Care Excellence]] (NICE), and the US's [[National Multiple Sclerosis Society]], endorsed the off-label use of modafinil to alleviate fatigue associated with MS in 2022.<ref name="The National Institute for Health and Care Excellence (NICE)-2022">{{cite web | url=https://www.nice.org.uk/guidance/ng220 | title=Multiple sclerosis in adults: Management, Guidance | publisher=The National Institute for Health and Care Excellence (NICE) | date=June 22, 2022 | access-date=September 5, 2022 | archive-date=September 5, 2022 | archive-url=https://web.archive.org/web/20220905191147/https://www.nice.org.uk/guidance/ng220 | url-status=live }}</ref><ref name="National Multiple Sclerosis Society">{{cite web |url=https://www.nationalmssociety.org/Treating-MS/Medications/Provigil |title=Provigil |publisher=National Multiple Sclerosis Society |access-date=September 6, 2022 |archive-date=September 5, 2022 |archive-url=https://web.archive.org/web/20220905191147/https://www.nationalmssociety.org/Treating-MS/Medications/Provigil |url-status=live }}</ref>

MS-related fatigue is a common and often debilitating symptom experienced by people with multiple sclerosis.<ref name="pmid35572947">{{cite journal |vauthors=Ayache SS, Serratrice N, Abi Lahoud GN, Chalah MA |title=Fatigue in Multiple Sclerosis: A Review of the Exploratory and Therapeutic Potential of Non-Invasive Brain Stimulation |journal=Front Neurol |volume=13 |pages=813965 |date=2022 |pmid=35572947 |pmc=9101483 |doi=10.3389/fneur.2022.813965 |doi-access=free }}</ref><ref name="pmid34856949">{{cite journal |vauthors=Oliva Ramirez A, Keenan A, Kalau O, Worthington E, Cohen L, Singh S |title=Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review |journal=BMC Neurol |volume=21 |issue=1 |pages=468 |date=December 2021 |pmid=34856949 |pmc=8638268 |doi=10.1186/s12883-021-02396-1 |doi-access=free }}</ref> It can significantly impact their daily functioning, [[quality of life]], and ability to perform everyday activities. When prescribed for MS-related fatigue management, modafinil works by promoting wakefulness and increasing [[alertness]] without causing drowsiness or disrupting nighttime sleep. People with multiple sclerosis often report increased energy levels, reduced feelings of tiredness, improved cognitive function, and an overall improvement in their quality of life when taking modafinil.<ref name="pmid38988104">{{cite journal |vauthors=Ghazanfar S, Farooq M, Qazi SU, Chaurasia B, Kaunzner U |title=The use of modafinil for the treatment of fatigue in multiple sclerosis: A systematic review and meta-analysis of controlled clinical trials |journal=Brain Behav |volume=14 |issue=7 |pages=e3623 |date=July 2024 |pmid=38988104 |pmc=11237168 |doi=10.1002/brb3.3623 }}</ref> While modafinil can provide relief from MS-related fatigue symptoms,<ref name="pmid38988104"/> it does not treat the underlying cause or cure MS itself.